Oxycodone hcl 5 mg
Pro Research Analysisby 
Searched over 200M research papers
Efficacy and Safety of Oxycodone HCl 5 mg for Postoperative Pain Management
Introduction to Oxycodone HCl 5 mg
Oxycodone hydrochloride (HCl) is a potent opioid analgesic commonly used to manage moderate-to-severe pain, particularly in postoperative settings. This article synthesizes recent research on the efficacy and safety of oxycodone HCl, specifically focusing on the 5 mg dosage.
Efficacy of Oxycodone HCl 5 mg in Postoperative Pain
Pain Relief and Intensity Reduction
Research has demonstrated that oxycodone HCl 5 mg is effective in reducing pain intensity in postoperative patients. A study evaluating oxycodone HCl/niacin tablets for postoperative pain following bunionectomy surgery found that a dose of 5 mg, when combined with niacin, significantly reduced pain intensity compared to placebo. The primary efficacy endpoint, the sum of pain-intensity difference scores over 48 hours (SPID48), showed superior pain relief with oxycodone HCl 5 mg/niacin tablets (p < 0.0001)1.
Comparison with Other Analgesics
Oxycodone HCl has been compared with other analgesics, including its combination with paracetamol (acetaminophen). A review of single-dose oral oxycodone, with or without paracetamol, for acute postoperative pain in adults indicated that doses exceeding 5 mg provided significant analgesia. Specifically, oxycodone 10 mg combined with paracetamol 650 mg had a number-needed-to-treat-to-benefit (NNT) of 2.7, demonstrating enhanced efficacy compared to oxycodone alone2.
Safety Profile of Oxycodone HCl 5 mg
Adverse Events and Tolerability
The safety profile of oxycodone HCl 5 mg has been well-documented. In the study on oxycodone HCl/niacin tablets, adverse events (AEs) were consistent with the known effects of oxycodone and niacin, with most AEs being mild to moderate in intensity. Importantly, no serious AEs were reported, and discontinuations due to AEs were minimal (1.5% in the 5 mg group)1.
Comparison with Placebo
When compared to placebo, oxycodone HCl 5 mg showed a higher incidence of AEs, but these were generally mild to moderate and rarely led to withdrawal from the study. This aligns with findings from the review of single-dose oral oxycodone, which also reported a higher frequency of AEs with combination therapy compared to placebo, yet described them as mild to moderate in severity2.
Conclusion
Oxycodone HCl 5 mg is an effective and generally well-tolerated option for managing moderate-to-severe postoperative pain. Its efficacy is enhanced when combined with other analgesics like paracetamol, providing significant pain relief with a manageable safety profile. These findings support the use of oxycodone HCl 5 mg in clinical settings for postoperative pain management.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery
Oxycodone HCl/niacin tablets (5/30 mg and 7.5/30 mg) effectively reduce moderate-to-severe postoperative pain and are generally well-tolerated in patients after bunionectomy surgery.
RCT
Large Human TrialSingle dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults.
Single dose oxycodone is effective in acute postoperative pain at doses over 5 mg, and when combined with paracetamol, provides good analgesia to half of those treated, comparable to commonly used non-steroidal anti-inflammatory drugs.
Systematic Review
Very Rigorous Journal
Highly CitedSingle dose oxycodone and oxycodone plus paracetamol (acetominophen) for acute postoperative pain.
Single-dose oral oxycodone, with or without paracetamol, is comparable to intramuscular morphine and non-steroidal anti-inflammatory drugs for acute postoperative pain, but central nervous system adverse effects are common.
Meta-AnalysisEfficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Tapentadol IR and oxycodone HCl IR both significantly reduce pain intensity in patients awaiting joint replacement surgery due to end-stage joint disease, with a higher tolerability.
RCTLarge Human TrialHighly CitedCombination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: a double-blind, placebo- and active-controlled parallel-group study.
A single dose of oxycodone 5 mg/ibuprofen 400 mg is fast-acting, effective, and well-tolerated for moderate to severe pain after dental surgery.
RCTLarge Human TrialAnalgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-
Oxycodone 5 mg/ibuprofen 400 mg provides significantly greater analgesia compared to oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain.
RCTHighly CitedSubjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products.
The 10-mg oxycodone/650 mg acetaminophen combination produces more significant subjective effects than the 5-mg hydrocodone combination, and both drugs impair psychomotor performance.
RCTComparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride
Tapentadol IR (50 mg, 75 mg) provides comparable pain relief and superior gastrointestinal tolerability compared to oxycodone hydrochloride, with lower incidences of nausea and vomiting.
RCT
Rigorous JournalSuccessful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo.
Oxycodone effectively treats idiopathic restless legs syndrome and periodic limb movements in sleep, improving sleep efficiency and patient preference over placebo.
RCTHighly CitedEfficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.
Controlled-release oxycodone effectively manages steady, paroxysmal spontaneous pain, and allodynia in postherpetic neuralgia patients, providing pain relief and improving overall quality of life.
RCTHighly Cited